间日疟疾治疗的关键是根治。因为这不仅关系到迅速解除病人痛苦,保证病人及时恢复健康;而且关系到能否及时消灭传染源、防止疟疾传播流行的问题。近几十年来国内外普遍应用的氯化喹啉(以下简称氯喹)和伯氨喹啉(以下简称伯喹)配伍疗法,由于耐药性及耐药虫株的产生,已使该疗法的疗程由三日改为五日,近几年来又改为八日。不但疗程长、副作用大难以推行,而且根治率在某些地区也越来越低。因此寻求新的根治药物及新疗法,已成为国内疟疾防治工作者近几年来研究的重点。中国医学科学院寄生虫病研究所,曾于1970年合成了一种抗疟新药——磷酸咯萘啶(简称“7351”), The key to inter-day malaria treatment is cure. This is not only related to the prompt resolution of the patient’s suffering and the timely recovery of the patient’s health, but also to the timely elimination of the source of infection and the prevention of the spread of malaria. In recent decades, the commonly used domestic and international quinoline chloride (hereinafter referred to as chloroquine) and primary quinoline (hereinafter referred to as primary Qu) compatibility therapy, due to drug resistance and the emergence of resistant strains of insects, has made the treatment of the therapy From three days to five days, in recent years it was changed to eight days. Not only long course of treatment, the side effects of large difficult to implement, and the cure rate is getting lower and lower in some areas. Therefore, seeking new cure drugs and new therapies has become the focus of research on malaria prevention and treatment in China in recent years. Institute of Parasitic Diseases, Chinese Academy of Medical Sciences, in 1970 synthesized a new antimalarial - pyronaridine phosphate (referred to as “7351”),